Market closedNon-fractional
Aligos Therapeutics/ALGS
13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1YMAX
About Aligos Therapeutics
Aligos Therapeutics Inc is a clinical-stage biopharmaceutical company. It is engaged in developing novel therapeutics to address unmet medical needs in viral and liver diseases, including chronic hepatitis B and coronaviruses, and therapeutics for nonalcoholic steatohepatitis (NASH). The company's pipeline includes ALG-010133, ALG-000184, ALG-020572 and ALG-055009, among others.
Ticker
ALGS
Sector
Healthcare
Trading on
NASDAQ
Industry
Biotechnology
Headquarters
South San Francisco, United States
Employees
67
Website
www.aligos.com
ALGS Metrics
BasicAdvanced
$32M
Market cap
-
P/E ratio
-$1.08
EPS
2.37
Beta
-
Dividend rate
Price and volume
Market cap
$32M
Beta
2.37
Financial strength
Current ratio
6.253
Quick ratio
5.971
Long term debt to equity
12.059
Total debt to equity
17.535
Management effectiveness
Return on assets (TTM)
-42.83%
Return on equity (TTM)
-137.79%
Valuation
Price to revenue (TTM)
2.712
Price to book
0.51
Price to tangible book (TTM)
0.51
Price to free cash flow (TTM)
-0.471
Growth
Revenue change (TTM)
-1.90%
Earnings per share change (TTM)
-44.79%
3-year revenue growth
147.47%
3-year earnings per share growth
-44.28%
What the Analysts think about ALGS
Analyst Ratings
Majority rating from 1 analysts.
ALGS Financial Performance
Income StatementBalance sheetCash Flow
Income Statement
Revenues and expenses
QuarterlyAnnual
Q1 24
QoQ growth
Revenue
$900K
-65.38%
Net income
-$35M
25.18%
Profit margin
-3,866.66%
261.63%
ALGS Earnings Performance
Earnings per share (EPS)
Company profitability
QuarterlyAnnual
Q2 23
Q3 23
Q4 23
Q1 24
Q2 24
Actual
-$0.43
-$0.41
-$0.22
-$0.22
-
Expected
-$0.50
-$0.48
-$0.27
-$0.19
-$0.16
Surprise
-13.13%
-13.68%
-18.52%
15.79%
-
ALGS News
AllArticlesVideos
Aligos Therapeutics Presents Positive Data at the EASL Congress 2024
GlobeNewsWire·1 month ago
Aligos Therapeutics Announces Six Abstracts Accepted for Presentation at EASL 2024
GlobeNewsWire·1 month ago
Aligos Therapeutics Announces the Completion of Enrollment in the ALG-055009 Phase 2a HERALD Study for the Treatment of MASH
GlobeNewsWire·2 months ago
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real time US market data is a consolidated feed of IEX, NYSE National, NYSE Chicago, Nasdaq BX and Nasdaq PSX order books provided by Polygon
Market closedNon-fractional
Upcoming events
No upcoming events
FAQs
What’s the current market cap for Aligos Therapeutics stock?
Aligos Therapeutics (ALGS) has a market cap of $32M as of July 06, 2024.
What is the P/E ratio for Aligos Therapeutics stock?
The price to earnings (P/E) ratio for Aligos Therapeutics (ALGS) stock is 0 as of July 06, 2024.
Does Aligos Therapeutics stock pay dividends?
No, Aligos Therapeutics (ALGS) stock does not pay dividends to its shareholders as of July 06, 2024.
When is the next Aligos Therapeutics dividend payment date?
Aligos Therapeutics (ALGS) stock does not pay dividends to its shareholders.
What is the beta indicator for Aligos Therapeutics?
Aligos Therapeutics (ALGS) has a beta rating of 2.37. This means that it is more volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 2 would indicate the stock moves twice as much as the market.
Buy or sell Aligos Therapeutics stock
Stocks, funds and up to 4.50% interest earned on uninvested cash. When you invest, your capital is at risk.